RAPT — Rapt Therapeutics Share News
0.000.00%
Last trade - 00:00Deals of the day-Mergers and acquisitions
Live Markets: STOXX hits 2-week low as volatility jumps
RAPT Therapeutics shares surge ~65% premarket on $2.2 bln GSK buyout
Live Markets: Before the bell: EU futures dip, French drink makers eyed
GSK to buy RAPT Therapeutics for $2.2 billion (updated)
Brief: GSK To Acquire RAPT Therapeutics For $2.2 Bln
GSK to buy RAPT Therapeutics for $2.2 billion
Rapt Therapeutics Q3 net loss narrows as R&D costs drop
Brief: Rapt Therapeutics Initiates Phase 2B Clinical Trial Of Ozureprubart In Patients With Food Allergies
RAPT Therapeutics slides after $250 mln stock offering
Brief: RAPT Therapeutics Announces Pricing Of Public Offering Of 8.3 Million Shares At $30.00 Each
Brief: Rapt Therapeutics Announces Proposed Public Offering Of Common Stock
U.S. RESEARCH ROUNDUP-Block, Morgan Stanley, W R Berkley
U.S. STOCKS ON THE MOVE-Arm Holdings, silver miners, Zions Bancorp
RAPT rallies as skin condition drug shows comparable efficacy to Roche's drug
U.S. STOCKS ON THE MOVE-Apple, Zoom, Arm Holdings
RAPT Therapeutics soars as skin condition drug shows comparable efficacy to Roche's drug
Brief: Rapt Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of Rpt904 (Jyb1904) in Chronic Spontaneous Urticaria
Brief: RAPT Therapeutics Announces FDA Clearance to Proceed to Phase 2b Trial of RPT904 in Food Allergy